EUVIMEDEUVIMED entdecken
Crossref

Double-Filtration Plasmapheresis for ABO-Incompatible Living-Donor Kidney Transplantation

Xiaochun Zhou, Youmin Yang, Yingying Yang, Yunying Shi, Xi Tang, Xu Li, Fang Wang, Ping Fu, Xianding Wang, Ling Zhang

Blood Purification · 16.05.2026 · 1-12

DOI: 10.1159/000552433 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Blood Purification, online erschienen am 16.05.2026. Verfasst von Xiaochun Zhou und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nephrology and Institute of Kidney Diseases, West China Hospital, Sichuan University, Chengdu, China. Die Arbeit nennt 31 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

ABO-incompatible (ABOi) kidney transplantation (KT) is now an established form of renal replacement therapy. However, it is important to note that ABO antibody clearance affects the procedure’s success. As demonstrated in prior studies, both double-filtration plasmapheresis (DFPP) and plasma exchange (PE) can eliminate IgM and IgG isoagglutinins. However, relatively few studies have examined the long-term prognosis in patients with both conditions. The present study aimed to compare the efficacy and long-term prognosis of DFPP with those of PE in patients with ABOi-KT.

Methods

From September 2014 to April 2024, 230 consecutive ABOi living-donor KTs were performed. The participants were divided into DFPP and PE groups. Following propensity score matching (PSM), the primary outcomes included acute rejection (AR), infection, graft loss, patient death, and the effects of the two modalities on isoagglutinin titers (IgG and IgM).

Results

After 1:4 PSM, a total of 24 patients in the PE group and 63 patients in the DFPP group were included in the final analysis. Compared with PE, DFPP was associated with a significantly lower incidence of 6-month AR (6.3% vs. 33.3%, p = 0.003) and 6-month patient mortality (0% vs. 12.5%, p = 0.019), along with shorter hospital stays (22 [18–29] vs. 42 [36–48] days, p < 0.001). Multifactorial analysis revealed that the risk of AR in ABOi-KTs with antibody rebound was 6.43 times greater than that in ABOi-KTs without antibody rebound (OR = 6.43, 95% CI: 1.21–34.1, p = 0.029), whereas the risk of AR in ABOi-KTs pretreated with DFPP was 85.8% lower than that in ABOi-KTs pretreated with PE (OR = 0.142, 95% CI: 0.04–0.57, p = 0.006). However, no statistically significant differences were observed between the two groups in 6-month creatinine levels or 6-month graft loss. No significant differences were observed between the two groups in the reduction of IgG and IgM isoagglutinins. A single PE session led to a reduction in the IgM isoagglutinin titer by approximately 3-fold, in comparison with a 2-fold reduction that was observed with a single session of DFPP. Similarly, a single PE session led to a 2-fold reduction in IgG isoagglutinin titer. DFPP sessions resulted in a reduction that was marginally less than 2-fold. It is noteworthy that DFPP exhibited a more pronounced depletion of albumin (10.6 ± 6.7 vs. 4.8 ± 5.5 g/L, p < 0.001), globulin (10.4 ± 6.5 vs. 5.5 ± 5.7 g/L, p = 0.002), and fibrinogen (1.5 [1.2–2.2] vs. 1.1 [0.1–1.9] g/L, p = 0.024).

Conclusions

Compared with PE, DFPP might be more advantageous in the ABOi-KT preconditioning regimen, but close monitoring of fibrinogen, albumin, and globulin is needed.

Schlagwörter

Stichwörter der Autor:innen

ABO-incompatible kidney transplantationDouble-filtration plasmapheresisIsoagglutininsKidney transplantationPlasma exchange

Autor:innen und Institutionen

  • Department of Nephrology and Institute of Kidney Diseases, West China Hospital, Sichuan University, Chengdu, China.
  • Department of Nephrology, Guang Han Hospital of Traditional Chinese Medicine, Deyang, China.
  • Department of Urology, Institute of Urology, Organ Transplantation Centre, West China Hospital, Sichuan University, Chengdu, China.
  • Department of Urology, Institute of Urology, Organ Transplantation Centre, West China Hospital, Sichuan University, Chengdu, China, xiandingwang@outlook.com.
  • Department of Nephrology and Institute of Kidney Diseases, West China Hospital, Sichuan University, Chengdu, China, zhangling_crrt@163.com.

Zitieren

APA

Zhou, X., Yang, Y., Yang, Y., Shi, Y., Tang, X., Li, X., Wang, F., Fu, P., Wang, X., & Zhang, L. (2026). Double-Filtration Plasmapheresis for ABO-Incompatible Living-Donor Kidney Transplantation. Blood Purification, 1-12. https://doi.org/10.1159/000552433

Vancouver

Zhou X, Yang Y, Yang Y, Shi Y, Tang X, Li X, et al. Double-Filtration Plasmapheresis for ABO-Incompatible Living-Donor Kidney Transplantation. Blood Purification. 2026:1-12. doi:10.1159/000552433

BibTeX
@article{Zhou2026,
  author = {Zhou, Xiaochun and Yang, Youmin and Yang, Yingying and Shi, Yunying and Tang, Xi and Li, Xu and Wang, Fang and Fu, Ping and Wang, Xianding and Zhang, Ling},
  title = {Double-Filtration Plasmapheresis for ABO-Incompatible Living-Donor Kidney Transplantation},
  journal = {Blood Purification},
  year = {2026},
  pages = {1--12},
  doi = {10.1159/000552433}
}
Kostenlos starten →